399 Phase I dose escalation and expansion study of PRAME T-cell receptor engineered IL15-transduced cord blood-derived natural killer cells in patients with recurrent/refractory melanoma (PRAMETIME-Mel)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Biology

Cancer Oncology

Medicine

Astrobiology

Cancer Research

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0399

License

CC-BY-NC

Other Formats

PDF